Aeterna Zentaris Announces Results of Virtual 2023 Meeting of Shareholders
2023年6月15日 - 5:05AM
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) ("Aeterna" or the
"Company"), a specialty biopharmaceutical company developing and
commercializing a diversified portfolio of pharmaceutical and
diagnostic products, today announced that all items of business
were approved at its virtual Annual General and Special Meeting of
Shareholders (the "AGM") held today.
Results of the AGM
At the AGM, all items of business were approved.
The individuals noted below were elected as directors of the
Company:
Name of Nominee |
Votes For |
% |
Votes Against |
% |
Peter Edwards |
401,912 |
68.94 |
% |
181,057 |
31.06 |
% |
Carolyn Egbert |
296,499 |
50.86 |
% |
286,470 |
49.14 |
% |
Gilles Gagnon |
402,690 |
69.08 |
% |
180,279 |
30.92 |
% |
Dr. Klaus Paulini |
317,211 |
54.41 |
% |
265,758 |
45.59 |
% |
Dennis Turpin |
298,514 |
51.21 |
% |
284,455 |
48.79 |
% |
At the AGM, Deloitte LLP was appointed as the
Company's auditor.
The Company is an "Eligible Interlisted Issuer"
as such term is defined in the TSX Company Manual. As an Eligible
Interlisted Issuer, the Company has relied on an exemption pursuant
to Section 602.1 of the TSX Company Manual from Section 613 of the
TSX Company Manual, the effect of which is that, subject to the
satisfaction of certain conditions prescribed by the Toronto Stock
Exchange, the Company will not have to comply with certain Canadian
requirements in connection with the Company's long-term incentive
plan. As a result, shareholders were not asked to approve the
unallocated entitlements under the Company's long-term incentive
plan at the AGM.
For full voting details, please see the report
of voting results filed on SEDAR at www.sedar.com and EDGAR at
www.sec.gov.
About Aeterna Zentaris Inc.
Aeterna Zentaris is a specialty
biopharmaceutical company developing and commercializing a
diversified portfolio of pharmaceutical and diagnostic products
focused on areas of significant unmet medical need. The Company's
lead product, macimorelin (Macrilen®; Ghryvelin™), is the first and
only U.S. FDA and European Commission approved oral test indicated
for the diagnosis of adult growth hormone deficiency (AGHD). The
Company is leveraging the clinical success and compelling safety
profile of macimorelin to develop it for the diagnosis of
childhood-onset growth hormone deficiency (CGHD), an area of
significant unmet need.
Aeterna Zentaris is dedicated to the development
of its therapeutic asset and has established a pre-clinical
development pipeline to potentially address unmet medical needs
across a number of indications, including neuromyelitis optica
spectrum disorder (NMOSD), Parkinson's disease (PD),
hypoparathyroidism and amyotrophic lateral sclerosis (ALS; Lou
Gehrig's disease).
For more information, please visit
www.zentaris.com and connect with the Company on Twitter, LinkedIn
and Facebook.Forward-Looking StatementsThis press
release contains statements that may constitute forward-looking
statements within the meaning of U.S. and Canadian securities
legislation and regulations and such statements are made pursuant
to the safe-harbor provision of the U.S. Securities Litigation
Reform Act of 1995. Forward-looking statements are frequently, but
not always, identified by words such as "expects," "anticipates,"
"believes," "intends," "potential," "possible," and similar
expressions. Such statements, based as they are on current
expectations of management, inherently involve numerous risks,
uncertainties and assumptions, known and unknown, many of which are
beyond our control. Forward-looking statements in this press
release include statements regarding the holding of, attending, and
voting before and at, the AGM. Forward-looking statements involve
known and unknown risks and uncertainties, and other factors which
may cause the actual results, performance or achievements stated
herein to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking information. Investors should consult our quarterly
and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties,
including those risks discussed in our Annual Report on Form 20-F
and annual information form, under the caption "Risk Factors".
Given the uncertainties and risk factors, readers are cautioned not
to place undue reliance on these forward-looking statements. We
disclaim any obligation to update any such factors or to publicly
announce any revisions to any of the forward-looking statements
contained herein to reflect future results, events or developments,
unless required to do so by a governmental authority or applicable
law. No securities regulatory authority has either approved or
disapproved of the contents of this news release. The Toronto Stock
Exchange accepts no responsibility for the adequacy or accuracy of
this release.Investor Contact:
Jenene ThomasJTC TeamT: +1 (833) 475-8247E: aezs@jtcir.com
Aeterna Zentaris (TSX:AEZS)
過去 株価チャート
から 4 2024 まで 5 2024
Aeterna Zentaris (TSX:AEZS)
過去 株価チャート
から 5 2023 まで 5 2024